CRISPR Therapeutics (NasdaqGM:CRSP) is entering a second phase of its business as the CASGEVY commercial rollout gains ...

Q1 results and earnings estimate revisions put CRISPR Therapeutics (CRSP) in focus CRISPR Therapeutics (CRSP) has moved back onto investors’ radar after reporting a Q1 2026 net loss of US$122.9 ...

A new preclinical model using CRISPR, an advanced technology that allows scientists to cut and edit genes, has given Weill Cornell Medicine researchers and their colleagues a deeper insight into how ...

Creative Biolabs updates its CRISPR-based gene editing and customized donor vector construction services to accelerate disease modeling and targeted gene therapy research worldwide.

New CRISPR approach: HKUST scientists created a DNA-guided CRISPR-Cas12a system that targets RNA, overturning the traditional RNA-guided DNA model. Diagnostic potential: The SLEUTH platform showed ...

Cas12a2, an RNA-triggered system that selectively kills cancer and virus-infected cells by inducing extensive DNA damage ...

New Haven, Conn. — Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But ...

Advances in CRISPR/Cas9 gene-editing have enabled researchers to easily and accurately make genetic modifications to human DNA. Meanwhile, the ability to reprogram cells into induced pluripotent stem ...

ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter ...

An international research team led by Dr Ana Guadaño at the Alberto Sols Biomedical Research Institute (IIBM, a combined CSIC-UAM center) and involving the Complutense University of Madrid (UCM), used ...